
Real-World Lung Cancer Data Links Biomarker Status to Survival and Medication Costs
Patients with advanced non–small cell lung cancer (NSCLC) experience markedly different survival outcomes and treatment costs depending on their tumor biomarker status, according to a new study led by Juanyi Tan, MPH. The findings, published earlier this …